32 completed, 17 recruiting, 13 unknown, 9 active not recruiting. 27 Phase 2, 15 Phase 3, 4 Phase 1, 3 Not applicable, 1 Phase 4.
Follow Hepatitis D: new trials by email Literature Review of Hepatitis D trials Research Report on Hepatitis D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic | Phase 3 | Not yet recruiting | Shanghai HEP Pharmaceutical Co., Ltd. | 150 | 2027-06-01 | 2026-10-28 |
| Hepatitis B Infection Surveillance Chronic Hepatitis B Infection | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1360 | 2026-09-01 | 2026-07-27 | |
| Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody: a Phase 1b, Open-label Trial in Individuals With Chronic Hepatitis D Infection HepB mAb19 - Hepatitis D, Chronic, Hepatitis B Chronic Infection | Phase 1 | Recruiting | Aarhus University Hospital | 15 | 2026-04-23 | 2026-05-28 |
| A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study) Libevitug 20 mg/kg, Libevitug 10 mg/kg, Delayed treatment with libevitug - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Huahui Health | 160 | 2026-04-22 | 2026-08-24 |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D | Phase 2 / Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 120 | 2026-02-26 | 2026-10-27 |
| Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D Bulevirtide, No intervention - HEPATITIS B CHRONIC, Hepatitis D | Recruiting | Research Center of Periodontal-Systemic Interactions | 25 | 2026-02-15 | 2026-03-25 | |
| A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg - Chronic Hepatitis D Infection | Phase 3 | Active not recruiting | Mirum Pharmaceuticals, Inc. | 80 | 2026-01-14 | 2026-06-29 |
| "Referral Attivo" Delta, Dallo Screening Alla Presa in Carico. Hepatitis, Delta | Recruiting | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 244 | 2025-10-01 | 2026-07-09 | |
| Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France Community screening for hepatitis B, C and delta in the Mongolian population living in France - HEPATITIS C (HCV), Hepatitis B Virus (HBV) | Not applicable | Not yet recruiting | Hospices Civils de Lyon | 2000 | 2025-09-01 | 2025-06-26 |
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 172 | 2025-08-27 | 2026-10-08 |
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 100 | 2025-08-05 | 2026-01-16 |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus GS-4321, GS-4321 Placebo - Chronic Hepatitis Delta | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 200 | 2025-07-31 | 2026-08-27 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg - Chronic Hepatitis D Infection | Phase 2 / Phase 3 | Active not recruiting | Mirum Pharmaceuticals, Inc. | 150 | 2025-03-25 | 2026-10-27 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Tobevibart, Elebsiran - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 124 | 2025-03-12 | 2026-11-03 |
| HDV Screening Study Hepatitis D Virus Infection | Recruiting | Grace Lai Hung Wong | 300 | 2025-02-15 | 2025-03-24 | |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants ABI-6250, Placebo - Hepatitis Delta Virus, Hepatitis D | Phase 1 | Completed | Assembly Biosciences | 40 | 2025-01-31 | 2025-12-04 |
| MIGrant Reflex Test HDV (MIGRED) Project anti-HDV positive with the reflex testing methodology - Hepatitis D Virus Infection | Not yet recruiting | University of Campania Luigi Vanvitelli | 7500 | 2024-12-20 | 2024-12-18 | |
| A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D hepalatide - Hepatitis D | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 90 | 2024-12-11 | 2026-10-29 |
| Determination of New Detection and Quantification Thresholds for Serological and Molecular Tests for Hepatitis Delta Virus (HDV) Using Capillary Blood on Blotting Paper (DBS) Dried Blood Spot, Analysis on plasma - Delta Hepatitis | Not applicable | Not yet recruiting | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | 120 | 2024-11-30 | 2024-10-18 |
Showing 20 of 85. Sign in to see all of them.
Hepatitis D, Chronic (36) · Hepatitis B (17) · Hepatitis B, Chronic (9) · Hepatitis (7) · Liver Cirrhosis (7) · Liver Diseases (6) · Carcinoma, Hepatocellular (5) · Fibrosis (5) · Hepatitis C (5) · Hepatitis, Chronic (4) · Digestive System Diseases (2) · Hepatitis, Alcoholic (2) · Acquired Immunodeficiency Syndrome (1) · Esophageal and Gastric Varices (1)
Hepatitis, Viral, Human (85) · Infections (85) · Virus Diseases (85) · RNA Virus Infections (84) · Digestive System Diseases (83) · Liver Diseases (79) · Hepatitis (78) · Pathologic Processes (50) · Pathological Conditions, Signs and Symptoms (50) · Chronic Disease (43) · Disease Attributes (43) · Hepatitis, Chronic (39) · Blood-Borne Infections (24) · Communicable Diseases (24)
bulevirtide (14) · peginterferon alfa-2a (9) · Tenofovir (8) · lonafarnib (7) · Ritonavir (6) · Treatment Delay (3) · entecavir (3) · myrcludex-B (3) · peginterferon lambda-1a (3) · Ezetimibe (2) · Ribavirin (2) · tenofovir alafenamide (2) · ARC-520 (1) · Anti-HIV Agents (1) · Blood Specimen Collection (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · Mirum Pharmaceuticals, Inc. (5) · Eiger BioPharmaceuticals (4) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (4) · Hoffmann-La Roche (4) · Vir Biotechnology, Inc. (4) · Gilead Sciences (3) · Hannover Medical School (3) · National Taiwan University Hospital (3) · Shanghai HEP Pharmaceutical Co., Ltd. (3) · EIT Pharma, Inc. (2) · HepNet Study House, German Liverfoundation (2) · Replicor Inc. (2) · University of Alabama at Birmingham (2) · ANRS, Emerging Infectious Diseases (1)
Italy (20) · Germany (19) · United States (18) · France (17) · Romania (16) · Moldova (12) · Pakistan (10) · New Zealand (9) · Turkey (Türkiye) (9) · Bulgaria (8) · Spain (8) · Taiwan (8) · United Kingdom (8) · Israel (7) · Sweden (7)
Theo Heller, M.D. (3) · Christopher Koh, M.D. (2) · Michael J Vinikoor, MD (2) · Benjamin Maasoumy, MD (1) · Brian Murphy, MD, MPH (1) · David Apelian, MD, PhD, MBA (1) · Eduardo B Martins, MD, DPhil (1) · Eleonora Sfreddo (1) · Heiner Wedemeyer, MD, PhD (1) · Heiner Wedemeyer, MD,PhD (1)
PMID 30664876, PMID 41586499, PMID 30833068, PMID 37120031, PMID 38340811, PMID 39648559, PMID 10673308, PMID 17894318, PMID 18171224, PMID 19208358, PMID 2183511, PMID 22529690, PMID 23828202, PMID 24976701, PMID 26189433, PMID 27132170, PMID 27746337, PMID 27817147, PMID 28834623, PMID 28911765, PMID 28963781, PMID 28964701, PMID 30244215, PMID 30516520, PMID 31407130, PMID 31429940, PMID 31778167, PMID 32335166, PMID 32634548, PMID 32684365, PMID 33553968, PMID 33671730, PMID 33895531, PMID 34048594, PMID 34155795, PMID 36113537, PMID 37288712, PMID 37345876, PMID 37407002, PMID 37787009, PMID 38842520, PMID 39009085, PMID 39663120, PMID 39897611, PMID 40087915, PMID 41205755, PMID 41211943, PMID 41317314, PMID 41405233, PMID 41674894
2025 (3), 2019 (2), 2015 (1), 2023 (1), K01TW009998 (1)